- The report contains detailed information about Codexis, Inc. that gives an unrivalled in-depth knowledge about internal business-environment of the company: data about the owners, senior executives, locations, subsidiaries, markets, products, and company history.
- Another part of the report is a SWOT-analysis carried out for Codexis, Inc.. It involves specifying the objective of the company's business and identifies the different factors that are favorable and unfavorable to achieving that objective. SWOT-analysis helps to understand company’s strengths, weaknesses, opportunities, and possible threats against it.
- The Codexis, Inc. financial analysis covers the income statement and ratio trend-charts with balance sheets and cash flows presented on an annual and quarterly basis. The report outlines the main financial ratios pertaining to profitability, margin analysis, asset turnover, credit ratios, and company’s long-term solvency. This sort of company's information will assist and strengthen your company’s decision-making processes.
- In the part that describes Codexis, Inc. competitors and the industry in whole, the information about company's financial ratios is compared to those of its competitors and to the industry. The unique analysis of the market and company’s competitors along with detailed information about the internal and external factors affecting the relevant industry will help to manage your business environment. Your company’s business and sales activities will be boosted by gaining an insight into your competitors’ businesses.
- Also the report provides relevant news, an analysis of PR-activity, and stock price movements. The latter are correlated with pertinent news and press releases, and annual and quarterly forecasts are given by a variety of experts and market research firms. Such information creates your awareness about principal trends of Codexis, Inc. business.
About Codexis, Inc.
Codexis, Inc. develops proprietary biocatalysts that would revolutionize chemistry-based manufacturing processes across various industries.
The company has focused its biocatalyst development efforts on various markets, including pharmaceuticals and biofuels. It is pursuing funded collaborations in other bioindustrial markets, including carbon management, water treatment, and chemicals.
Products and Services
The companys products and services enable it to add value throughout the drug lifecycle, from preclinical development to clinical development and commercialization.
Codex Biocatalyst Panels: The company sells Codex Biocatalyst Panels to customers who are engaged in preclinical and clinical drug development to allow them to screen and identify possible biocatalytic manufacturing processes for their drug candidates. Its Codex Biocatalyst Panels are plates embedded with genetically various variants of its proprietary biocatalysts, which allow its customers to determine whether a biocatalyst produces a desired activity that is applicable to a particular process.
The companys Codex Biocatalyst Panels: allow innovators to screen and identify possible biocatalytic manufacturing processes for their drug candidates in-house, without the risks of disclosing the composition of their proprietary molecules before they have received patent protection; and generate data that the company can use to optimize biocatalysts for a particular reaction.
Biocatalyst screening services: The company supplies the customer with the biocatalyst or perform optimization services to improve the performance of the biocatalyst. Its screening services: allow innovators to screen and identify possible biocatalytic manufacturing processes through access to its biocatalyst libraries; and generate data that the company can use to optimize biocatalysts for a particular reaction. The company has provided screening services to various innovator and generic pharmaceutical manufacturers.
Biocatalyst optimization services: The company works with its innovator customers during preclinical and clinical development to customize proprietary biocatalysts, resulting in optimized biocatalysts that have been evolved specifically to perform a desired process according to a selective set of specifications. The companys biocatalyst optimization services: allow innovators to improve the manufacturing process as their drug candidates progress through preclinical and clinical development.
Biocatalysts: The company supplies varying quantities of its proprietary biocatalysts to pharmaceutical companies, from small to moderate quantities while they are optimizing their production processes, to larger quantities during later-stage clinical development and commercial scale drug production. The companys biocatalysts: enable innovators to manufacture products during preclinical and clinical development using optimized biocatalytic processes; eliminate the need for innovators to invest in the development of chemical synthesis routes during the development stage; reduce the risk of adverse effects arising from impurities; and allow the removal of entire steps from synthetic chemical production routes during commercial scale production.
Intermediates and APIs: The company supplies intermediates and APIs to its customers throughout the drug lifecycle. In the innovator market, the company intends to supply Pfizer with an intermediate in the scale-up and manufacture of a product candidate for upcoming clinical trials. The company also develops and, in partnership with Arch, manufactures and sells generic intermediates in the non-regulated markets. Its generics product portfolio and pipeline includes intermediates and APIs for infectious disease, cardiovascular and central nervous system indications, with expansion planned to a number of other therapeutic categories. It intends to sell this intermediate to manufacturers who would market the generic version of Lipitor in the United States and Europe once the composition of matter patents for Lipitor expire in those markets.
The company has entered into a technology transfer and s
The above Company Fundamental Report is a half-ready report and contents are subject to change.
It means that we have all necessary data in our database to prepare the report but need 2-3 days to complete it. During this time we are also updating the report with respect to the current moment. So, you can get all the most recent data available for the same price. Please note that preparation of additional types of analyses requires extra time.
1. CODEXIS, INC. COMPANY PROFILE
1.2. Financial Performance
1.3. Key Executives
1.4. Ownership and Major Holders
1.5. Company History
2. CODEXIS, INC. BUSINESS OVERVIEW
2.2. Major Products and Services
2.3. Markets and Sales Activities
2.4. Locations, Subsidiaries, Operating Units
3. CODEXIS, INC. SWOT ANALYSIS
4. CODEXIS, INC. FINANCIAL ANALYSIS
4.1.1. Income Statement
4.1.2. Balance Sheet
4.1.3. Cash Flow
4.2. Financial Ratios
4.2.2. Margin Analysis
4.2.3. Asset Turnover
4.2.4. Credit Ratios
4.2.5. Long-Term Solvency
4.2.6. Growth Over Prior Year
4.2.7. Financial Ratios Charts
4.3. Stock Market Snapshot
5. CODEXIS, INC. COMPETITORS AND INDUSTRY ANALYSIS
5.1. Codexis, Inc. Direct Competitors
5.2. Comparison of Codexis, Inc. and Direct Competitors Financial Ratios
5.3. Comparison of Codexis, Inc. and Direct Competitors Stock Charts
5.4. Codexis, Inc. Industry Analysis
5.4.1. Pharmaceuticals and Biotechnology Industry Snapshot
5.4.2. Codexis, Inc. Industry Position Analysis
6. CODEXIS, INC. NEWS & EVENTS
6.1. News & PR Activity Analysis
6.2. IR Corporate News
6.3. Marketing News
6.4. Corporate Events
7. CODEXIS, INC. EXPERTS REVIEW1
7.1. Experts Opinion
7.2. Experts Estimates
8. CODEXIS, INC. ENHANCED SWOT ANALYSIS2
9. UNITED STATES PESTEL ANALYSIS2
9.2. Economic Factors
9.3. Social Factors
9.4. Technological Factors
9.5. Environmental Factors
9.6. Legal Factors
10. CODEXIS, INC. IFE, EFE, IE MATRICES2
10.2. External Factor Evaluation Matrix
10.3. Internal External Matrix
11. CODEXIS, INC. PORTER FIVE FORCES ANALYSIS2
12. CODEXIS, INC. VRIO ANALYSIS2
APPENDIX: RATIO DEFINITIONS
LIST OF TABLES
Codexis, Inc. Key Facts
Income Statement Key Figures
Balance Sheet Key Figures
Cash Flow Statement Key Figures
Financial Performance Abbreviation Guide
Codexis, Inc. Key Executives
Key Executives Biographies1
Key Executives Compensations1
Codexis, Inc. Major Shareholders
Codexis, Inc. History
Codexis, Inc. Products
Revenues by Segment
Revenues by Region
Codexis, Inc. Offices and Representations
Codexis, Inc. SWOT Analysis
Yearly Income Statement Including Trends
Income Statement Latest 4 Quarters Including Trends
Yearly Balance Sheet Including Trends
Balance Sheet Latest 4 Quarters Including Trends
Yearly Cash Flow Including Trends
Cash Flow Latest 4 Quarters Including Trends
Codexis, Inc. Profitability Ratios
Margin Analysis Ratios
Asset Turnover Ratios
Long-Term Solvency Ratios
Financial Ratios Growth Over Prior Year
Codexis, Inc. Capital Market Snapshot
Codexis, Inc. Direct Competitors Key Facts
Direct Competitors Profitability Ratios
Direct Competitors Margin Analysis Ratios
Direct Competitors Asset Turnover Ratios
Direct Competitors Credit Ratios
Direct Competitors Long-Term Solvency Ratios
Pharmaceuticals and Biotechnology Industry Statistics
Codexis, Inc. Industry Position
Company vs. Industry Income Statement Analysis
Company vs. Industry Balance Sheet Analysis
Company vs. Industry Cash Flow Analysis
Company vs. Industry Ratios Comparison
Codexis, Inc. Consensus Recommendations1
Analyst Recommendation Summary1
Price Target Summary1
Experts Recommendation Trends1
Revenue Estimates Analysis1
Earnings Estimates Analysis1
Revenue Estimates Trend1
Earnings Estimates Trend1
LIST OF FIGURES
Codexis, Inc. Annual Revenues in Comparison with Cost of Goods Sold and Gross Profit
Profit Margin Chart
Operating Margin Chart
Return on Equity (ROE) Chart
Return on Assets (ROA) Chart
Debt to Equity Chart
Current Ratio Chart
Codexis, Inc. 1-year Stock Charts
Codexis, Inc. 5-year Stock Charts
Codexis, Inc. vs. Main Indexes 1-year Stock Chart
Codexis, Inc. vs. Direct Competitors 1-year Stock Charts
Codexis, Inc. Article Density Chart
2 – These sections are available only when you purchase a report with appropriate additional types of analyses.
The complete financial data is available for publicly traded companies.
Enhanced SWOT Analysis
- How to use the strengths to take advantage of the opportunities?
- How to use the strengths to reduce likelihood and impact of the threats?
- How to overcome the weaknesses that obstruct taking advantage of the opportunities?
- How to overcome the weaknesses that can make the threats a reality?
Key Factors Examined by PESTEL Analysis:
- Legal – What laws and legislation will exert influence on the style the business is carried out?
IFE, EFE, IE Matrices
Porter Five Forces Analysis
- What composes a threat of substitute products and services?
- Is there a threat of new competitors entering the market?
- What is the intensity of competitive rivalry?
- How big is the bargaining power of buyers?
- How significant is the bargaining power of suppliers?
- Tangible resources
- Intangible resources
- Innovation and Creativity
- Organizational capabilities
- Costly to imitate?
- Organized properly?